Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in...
-
Upload
melinda-nichols -
Category
Documents
-
view
216 -
download
0
Transcript of Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in...
![Page 1: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/1.jpg)
Consensus or Controversy?Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma
Friday, December 6, 20131:00 PM - 3:30 PM
New Orleans, Louisiana
Faculty Brad S Kahl, MDMitchell R Smith, MD, PhDSteven M Horwitz, MD
Michele E Ghielmini, MD, PhDLaurie H Sehn, MD, MPH
ModeratorNeil Love, MD
![Page 2: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/2.jpg)
MCL
![Page 3: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/3.jpg)
MCL induction for younger patients?
R-CHOP alternated w/ R-DHAP
NORDIC regimen
NORDIC regimen
Bendamustine/rituximab (BR)
Modified NORDIC regimen using standard R-CHOP, then R/HD cytarabine
NORDIC regimen = R/maxi-CHOP R/high-dose (HD) cytarabine
![Page 4: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/4.jpg)
70 yo with MCL receives BR. Moderately symptomatic disease progression after 18 months. 2nd-line treatment?
Bortezomib + rituximab
Ibrutinib
Ibrutinib
R-CVP, R-CHOP or R-GDP
Ibrutinib
R-GDP = Rituximab with gemcitabine/cisplatin/dexamethasone
![Page 5: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/5.jpg)
70 yo with MCL receives BR. Moderately symptomatic progression after 18 months. Receives 2nd-line bortezomib + rituximab and achieves PR but after 14 months has clinical disease progression. 3rd-line treatment?
Lenalidomide + rituximab
Ibrutinib
Ibrutinib
R-CVP, R-CHOP or R-GDP
Ibrutinib
R-GDP = Rituximab with gemcitabine/cisplatin/dexamethasone
![Page 6: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/6.jpg)
90 yo with symptomatic MCL: Up-front treatment?
Should ibrutinib be used up front for select patients with MCL?
Steroids
BR
Ibrutinib
Ibrutinib
R monotherapy
Up-front Tx
Yes
No
Yes
Yes
No
Use ibrutinib up front?
![Page 7: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/7.jpg)
Usual schedule and method of bortezomib administration in relapsed MCL?
Weekly, subQ
Twice weekly, subQ
Twice weekly, subQ
I don't use bortezomib for patients with MCL
Weekly, subQ
![Page 8: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/8.jpg)
75 yo with MCL: PR after 6 cycles of BR. Additional therapy?
None
R maintenance x 2 years
R maintenance x 2 years
R maintenance x 2 years
R maintenance x 2 years
![Page 9: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/9.jpg)
Proportion of MCL patients observed?
10%
5%
15%
5%
10%
![Page 10: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/10.jpg)
CLL
![Page 11: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/11.jpg)
55 yo with CLL: Usual 1st-line treatment? 1st-line treatment if del(17p)?
FCR
BR
FCR
FR
BR
1st-line Tx
FCR
FCR
FCR
FR
FCR
1st-line Tx, del(17p)
F = fludarabine; C = cyclophosphamide; R = rituximab
![Page 12: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/12.jpg)
How often do you use chlorambucil +/- rituximab for CLL?
Occasionally
Rarely
Rarely
Rarely
Occasionally
![Page 13: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/13.jpg)
80 yo with CLL: Usual 1st-line treatment? 1st-line treatment if del(17p)?
BR
BR
BR
Rituximab + chlorambucil
Rituximab + chlorambucil
Standard risk
Rituximab + chlorambucil
Alemtuzumab
Alemtuzumab
Rituximab + chlorambucil
Alemtuzumab
Del(17p)
![Page 14: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/14.jpg)
Efficacy of obinutuzumab vs rituximab in CLL?
Equally efficacious
Equally efficacious
Not enough information to answer
Obinutuzumab is more efficacious
Not enough information to answer
![Page 15: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/15.jpg)
Plan for use of obinutuzumab in CLL?
As monotherapy in relapsed disease
Not currently using, awaiting further data
Not currently using, awaiting further data
Up front with any chemotherapy
Select patients up front with chlorambucil
![Page 16: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/16.jpg)
Lenalidomide +/- rituximab for CLL?
Select patients in R/R setting
Select patients in R/R setting
Select patients in R/R setting
None
Select patients in R/R setting
R/R = relapsed/refractory
![Page 17: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/17.jpg)
TCL
![Page 18: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/18.jpg)
Usual induction for PTCL NOS?
CHOEP
CHOEP
CHOEP
CHOP alternating with GDP
CHOEP
![Page 19: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/19.jpg)
Older nontransplant-eligible patient with CD30-negative PTCL NOS. Asymptomatic, low tumor burden disease progression shortly after receiving CHOP. Usual next therapy outside of a protocol setting?
Gemcitabine
Pralatrexate or romidepsin
Romidepsin
GDP
Romidepsin
![Page 20: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/20.jpg)
In what situations do you recommend transplant in PTCL NOS? Recommended transplant type?
Consolidation after induction
Consolidation after induction; R/R disease and ≥PR after 2nd-line Tx
Consolidation after induction
R/R disease and ≥PR after 2nd-line Tx; Occasional pt at high risk after
induction
Consolidation after induction
Recommend transplant?
Autologous
Autologous or allogeneic, nonmyeloablative
Autologous
Autologous or allogeneic, myeloablative
Autologous
Type of transplant?
![Page 21: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/21.jpg)
For TCL or B-cell lymphomas do you recommend CD30 testing in a nonresearch, community setting?
At relapse
Up front and at relapse
At relapse
Pts w/ ALCL and select other pts
At relapse
TCL
No
At relapse
Will consider in elderly pt w/ relapsed large cell lymphoma
No
At relapse if post-SCT or SCT ineligible
B-cell lymphomas
![Page 22: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/22.jpg)
Proportion of patients receiving romidepsin who require dose reduction or discontinuation due to toxicity?
Most common dose-limiting side effects?
Have not used romidepsin
25%
70%
Have not used romidepsin
25%
Dose reduction/discontinuatio
n
N/A
Fatigue, nausea/vomiting
Fatigue
N/A
Fatigue, nausea/vomiting, thrombocytopenia
Dose-limiting side effects
![Page 23: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/23.jpg)
Proportion of patients receiving pralatrexate who require dose reduction or discontinuation due to toxicity?
Most common dose-limiting side effects?
Have not used pralatrexate
100%
90%
Have not used pralatrexate
50%
Dose reduction/discontinuatio
n
N/A
Mucositis
Mucositis
N/A
Mucositis
Dose-limiting side effects
![Page 24: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/24.jpg)
FL
![Page 25: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/25.jpg)
Younger patients with FL: Usual induction therapy?
Additional treatment for those responding to induction?
R monotherapy
BR
BR
BR
BR
Up-front Tx
R x 2 years
R x 2 years
R x 2 years
R x 2 years
R x 2 years
Additional Tx after induction
![Page 26: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/26.jpg)
Efficacy and tolerability of BR vs R-CHOP?
Similar for both
Similar for both
Similar for both
BR likely more efficacious
Similar for both
Efficacy
BR more tolerable
Similar for both
Similar for both
BR more tolerable
BR more tolerable
Tolerability
![Page 27: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/27.jpg)
Would you use R2 (lenalidomide/rituximab) in FL outside of a protocol setting?
Up front in select pts w/ low tumor burden
In select pts w/ recurrent disease and desire to avoid chemo
In select pts w/ recurrent disease after SCT or who are SCT ineligible
Would consider in select pts w/ no further Tx options
In select pts w/ recurrent or R/R disease after at least 2 lines of therapy
![Page 28: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/28.jpg)
Situations in which you use transplant in FL?
For pts in remission with negative bone marrow for FL, what type of transplant do you recommend?
Consolidation in 2nd remission
Consolidation in 2nd remission; transformation in 1st remission
Consolidation in 3rd remission; transformation in 1st remission
Consolidation in 3rd remission; transformation in 1st remission
Consolidation in 3rd remission; transformation in 1st remission
Recommend transplant?
Autologous
Autologous or allogeneic, nonmyeloablative
Autologous
Allogeneic, nonmyeloablative
Autologous
Type of transplant?
![Page 29: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/29.jpg)
DLBCL
![Page 30: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/30.jpg)
Use of lenalidomide +/- rituximab in DLBCL?
No
Occasionally for pts with ABC-type DLBCL in relapse
Yes, elderly patient w/ relapsed disease
No
Pts in relapse after alloSCT or in 2nd relapse and SCT ineligible
![Page 31: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/31.jpg)
DLBCL with disease progression s/p R-CHOP and ineligible for transplant: 2nd-line systemic treatment?
Bendamustine +/- rituximab
GEMOX +/- rituximab
GEMOX +/- rituximab
R-GDP
Bendamustine +/- rituximab
![Page 32: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/32.jpg)
Which biomarker assays should be used in general oncology practice for the management of DLBCL?
None
Ki-67, C-MYC, BCL-2, t(8;14)
C-MYC, BCL-2
C-MYC, BCL-2
Ki-67, CD20, C-MYC, t(8;14)
![Page 33: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/33.jpg)
Diagnostic tests you perform during active treatment for DLBCL?
PET-negative CR after 6 cycles of R-CHOP: Approach to follow-up scans?
CT
CT
CT
PET and CT
PET (end of treatment), CT (midtreatment)
Diagnostic test
Every 6 months x 2 years
Every 6 months x 2 years
Every 6 months x 2 years
I don't generally order follow-up scans for these patients
At 6, 12 and 24 months
Approach to follow-up scans
![Page 34: Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM.](https://reader038.fdocuments.us/reader038/viewer/2022103122/56649cec5503460f949b9289/html5/thumbnails/34.jpg)
Treatment for a patient with DLBCL, a history of cardiac disease and moderate cardiomyopathy?
R-CEOP
R-CEOP
R-CEOP
R-CEOP
R-CEOP